Hartmuth C. Kolb

Hartmuth C. Kolb

Auto-generated profile, based on publicly available information

Hartmuth C. Kolb

Siemens Molecular Imaging Biomarker Research, 6100 Bristol Parkway, Culver City, CA 90230 (USA)

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2014 in Antioxidants & Redox Signaling
Verified
Journal Article
Closed access
JWJoseph C. Walsh
Joseph C. Walsh
ALArtem Lebedev
Artem Lebedev
EAEdward Aten
Edward Aten
KMKathleen Madsen
Kathleen Madsen
LMLiane Marciano
Liane Marciano
HKHartmuth C. Kolb
Hartmuth C. Kolb
Tumor hypoxia is a well-established biological phenomenon that affects the curability of solid tumors, regardless of treatment modality. Especially for head and neck cancer patients, tumor hypoxia is linked to poor patient outcomes. Given the biological problems associated with tumor hypoxia, the goal for clinicians has been to identify moderately to severely hypoxic tumors for differential treatment strategies. The “gold standard” for detecting and characterizing of tumor hypoxia are the invasive polarographic electrodes. Several less invasive hypoxia assessment techniques have also shown promise for hypoxia assessment. The widespread incorporation of hypoxia information in clinical tumor assessment is severely impeded by several factors, including regulatory hurdles and unclear correlation with potential treatment decisions. There is now an acute need for approved diagnostic technologies for determining the hypoxia status of cancer lesions, as it would enable clinical development of personalized, hypoxia-based therapies, which will ultimately improve outcomes. A number of different techniques for assessing tumor hypoxia have evolved to replace polarographic pO2 measurements for assessing tumor hypoxia. Several of these modalities, either individually or in combination with other imaging techniques, provide functional and physiological information of tumor hypoxia that can significantly improve the course of treatment. The assessment of tumor hypoxia will be valuable to radiation oncologists, surgeons, and biotechnology and pharmaceutical companies who are engaged in developing hypoxia-based therapies or treatment strategies. Antioxid. Redox Signal. 21, 1516–1554. I. Introduction II. The Clinical Importance of Tumor Hypoxia A. Pathophysiology of hypoxia B. Hypoxia's negative impact on the effectiveness of curative treatment 1. Hypoxic tumors accumulate and propagate cancer stem cells 2. Hypoxia reduces the effectiveness of radiotherapy 3. Hypoxia increases metastasis risk and reduces the effectiveness of surgery 4. Hypoxic tumors are resistant to the effects of chemotherapy and chemoradiation C. Hypoxia is prognostic for poor patient outcomes III. Diagnosis of Tumor Hypoxia A. Direct methods 1. Oxygen electrode—direct pO2 measurement most used in cancer research 2. Phosphorescence quenching—alternative direct pO2 measurement 3. Electron paramagnetic resonance 4. 19F-magnetic resonance spectroscopy 5. Overhauser-enhanced MRI B. Endogenous markers of hypoxia 1. Hypoxia-inducible factor-1α 2. Carbonic anhydrase IX 3. Glucose transporter 1 4. Osteopontin 5. A combined IHC panel of protein markers for hypoxia 6. Comet assay C. Physiologic methods 1. Near-infrared spectroscopy/tomography—widely used for pulse oximetry 2. Photoacoustic tomography 3. Contrast-enhanced color duplex sonography 4. MRI-based measurements 5. Blood oxygen level-dependent MRI 6. Pimonidazole 7. EF5 (pentafluorinated etanidazole) 8. Hypoxia PET imaging—physiologic hypoxia measurement providing tomographic information a. 18F-fluoromisonidazole b. 18F-fluoroazomycinarabinofuranoside c. 18F-EF5 (pentafluorinated etanidazole) d. 18F-flortanidazole e. Copper (II) (diacetyl-bis (N4-methylthiosemicarbazone)) f. 18F-FDG imaging of hypoxia IV. Modifying Hypoxia to Improve Therapeutic Outcomes A. Use of hypoxia information in radiation therapy planning B. Use of hypoxia assessment for selection of patients responsive to nimorazole C. Use of hypoxia assessment for selection of patients responsive to tirapazamine D. Use of hypoxia assessment for selection of patients responsive to oxygen delivery therapies V. Concluding Remarks

29 October 2013 in Journal of Alzheimer’s Disease
Verified
Journal Article
Open access
PDF file
DCDavid T. Chien
David T. Chien
ASA. Katrin Szardenings
A. Katrin Szardenings
SBShadfar Bahri
Shadfar Bahri
JWJoseph C. Walsh
Joseph C. Walsh
FMFanrong Mu
Fanrong Mu
HKHartmuth C. Kolb
Hartmuth C. Kolb
Aggregates of hyperphosphorylated tau (PHF-tau), such as neurofibrillary tangles, are linked to the degree of cognitive impairment in Alzheimer's disease. We have recently reported early clinical results of a novel PHF-tau targeting PET imaging agent

3 December 2024 in Alzheimer's & Dementia
Verified
Journal Article
Open access
CTCharlotte E. Teunissen
Charlotte E. Teunissen
RKRachel Kolster
Rachel Kolster
GTGallen Triana‐Baltzer
Gallen Triana‐Baltzer
SJShorena Janelidze
Shorena Janelidze
HZHenrik Zetterberg
Henrik Zetterberg
HKHartmuth C. Kolb
Hartmuth C. Kolb
The revised biomarker framework for diagnosis and staging of Alzheimer's disease (AD) relies on amyloid beta (Aβ) and tau pathologies as core markers, and markers for adjacent pathophysiology, such as neurodegeneration and inflammation. Many of the core fluid biomarkers are phosphorylated tau (p‐tau) fragments, with p‐tau217 showing a prominent association with Aβ and tau. While positron emission tomography (PET) imaging is well established, plasma p‐tau assays are newer and likely to reduce the use of expensive, and less accessible cerebrospinal fluid and PET imaging tests, thereby promoting wider access to AD screening. There is a need for greater understanding of how the various plasma p‐tau species reflect different pathological processes of AD and how different immunoassays perform. This review surveys the available immunoassays and highlights their strengths and limitations in different contexts of use. Assays need to be standardized to maximize their impact on AD clinical research, and patient diagnosis and management. Highlights: Different plasma phosphorylated tau (p‐tau) species reflect different pathological processes of Alzheimer's disease (AD), with p‐tau231 showing the greatest association with the earliest increases in brain amyloid beta (Aβ) accumulation, while p‐tau217 shows greater association with both brain Aβ and early tau pathology, and other p‐tau and tau fragment species show greater association with later stages of brain tau pathology. Plasma p‐tau217 has proven to be an excellent biomarker for AD pathology due to its close association with both brain Aβ and tau pathology, as well as its large dynamic range. Many different assays with varying performance exist for the same p‐tau species, with mass spectrometry assays performing uniformly well, and several immunoassays achieving comparable performance. “Round robin” head‐to‐head studies have been performed to compare different assays for several key plasma biomarkers, including p‐tau181 and p‐tau217, but additional head‐to‐head studies are needed, especially for new analytes and for measuring performance in diverse populations. Plasma immunoassays have the potential to increase accessibility of early diagnostic testing for a broad population, including diverse historically under‐represented and under‐served populations, due to the potential to be implemented globally, including in primary care settings; however, further research is needed to validate the optimal cutoffs for each assay for real‐world clinical usage. Eventually, clinical implementation of a two‐step workflow may allow standalone use of plasma testing in certain contexts, minimizing the need for confirmation with costly and less accessible cerebrospinal fluid/positron emission tomography testing.

9 December 2016 in Cold Spring Harbor Perspectives in Biology
Verified
Journal Article
Open access
PDF file
HKHartmuth C. Kolb
Hartmuth C. Kolb
JAJosé Ignacio Andrés
José Ignacio Andrés
Alzheimer’s disease (AD) is a chronic neurodegenerative disorder and the most common cause of dementia among the elderly population. The good correlation between the density and neocortical spread of neurofibrillary tangles (NFTs) and the severity of cognitive impairment offers an opportunity to use a noninvasive imaging technique such as positron emission tomography (PET) for early diagnosis and staging of the disease. PET imaging of NFTs holds promise not only as a diagnostic tool but also because it may enable the development of disease-modifying therapeutics for AD. In this review, we focus on the structural diversity of tau PET tracers, the challenges related to identifying high-affinity and highly selective NFT ligands, and recent progress in the clinical development of tau PET radioligands.

21 May 2013 in Molecular Imaging and Biology
Verified
Journal Article
Closed access
PDF file
CXChun-Fang Xia
Chun-Fang Xia
GCGang Chen
Gang Chen
UGUmesh Gangadharmath
Umesh Gangadharmath
LGLuis F. Gomez
Luis F. Gomez
QLQianwa Liang
Qianwa Liang
HKHartmuth C. Kolb
Hartmuth C. Kolb

3 December 2012 in ChemMedChem
Verified
Journal Article
Closed access
PDF file
VMVani P. Mocharla
Vani P. Mocharla
JWJoseph C. Walsh
Joseph C. Walsh
HPHenry C. Padgett
Henry C. Padgett
HSHelen Su
Helen Su
BFBarbara Fueger
Barbara Fueger
HKHartmuth C. Kolb
Hartmuth C. Kolb